Ligand id: 6789

Name: etanercept

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: etanercept

1. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. (1998)
Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases.
Transplant. Proc., 30 (8): 4126-7. [PMID:9865320]
2. Goldenberg MM. (1999)
Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis.
Clin Ther, 21 (1): 75-87; discussion 1-2. [PMID:10090426]
3. Lee H, Chung H, Lee S, Lee H, Yang SM, Yoon SH, Cho JY, Jang IJ, Yu KS. (2017)
LBEC0101, A Proposed Etanercept Biosimilar: Pharmacokinetics, Immunogenicity, and Tolerability Profiles Compared with a Reference Biologic Product in Healthy Male Subjects.
BioDrugs, 31 (4): 349-355. [PMID:28551775]
4. Matsuno H, Tomomitsu M, Hagino A, Shin S, Lee J, Song YW. (2018)
Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
Ann. Rheum. Dis., 77 (4): 488-494. [PMID:29259050]